Maryland's 440 lifescience companies and 50 research-intense federal institutes make it a leader in the global lifescience sector. Turning research into reality are industry leaders like Human Genome Sciences, MedImmune, BD Diagnostics, BioReliance and QIAGEN.
The BioMaryland 2020 Strategic Plan, a $1.3 billion investment in the state’s life sciences industry over 10 years, will attract and grow the bioscience opportunities of tomorrow in Maryland. Recognized by the Milken Institute as top state bioscience development, the bioscience research community annually receives nearly $8 billion in research and development.
Recognized world-wide for its outstanding medical facilities, the state is home to nearly 50 acute care hospitals, ranking second nationally in physicians per 100,000 population with more than 23,000 doctors. Companies like Coventry Health Care, Catalyst Health Solutions and CareFirst of Maryland are among the state's leaders.
Peter A. Keiner, D.Phil., President & CEO of Zyngenia
Recognizing the need to develop better therapies for patients suffering from life threatening diseases, Peter A. Keiner, D.Phil came up with the idea to start an early stage pharmaceutical company. Convincing California based founder Carlos Barbas III, Ph.D that Maryland was the best place to develop this technology, Zyngenia was founded in 2008.